Renal denervation hogs the spotlight
Renal denervation systems, used to ablate the sympathetic nerves near the kidneys to control medication-resistant hypertension, got their own track at this year’s EuroPCR conference in Paris, where device titans showed off their devices and smaller companies hinted at things to come.
Medtronic (NYSE:MDT) and St. Jude Medical (NYSE:STJ) each unveiled new study results, vying for rank in the closely watched race to corner the market.
St. Jude announced CE Mark approval in the European Union for its Enlightn system on the opening day of the conference, later releasing early study results that hinted at a much greater reduction in blood pressure than achieved in by Medtronic’s Symplicity system in the same time-frame. Medtronic responded by dubbing the news “interesting,” but merely “hypothesis-generating,” noting that further studies are needed to draw any solid conclusions.
Smaller companies threw their hats into the ring as well, with ReCor Medical touting 3-month results for its Paradise ablation system, Vessix Vascular with 1-month results for its newly cleared device and Cardiosonic presenting animal data for its Tivus system.
Read more
A better outlook on stroke rates with TAVI
Better insight into how and when patients experience strokes following a transcatheter aortic valve implantation may help researchers bring down post-procedure stroke rates.
Read more
Biosensors’ self-expanding bifurcation stent looks good at 4 years
Biosensors’ Axxess self-expanding stent, used to treat complex coronary bifurcation lesions, showed low levels of major adverse cardiovascular events over a 4-year period.
Read more
